Agfa to employ DataFirst data migration, archiving tools

Justine Varieur Cadet | | Health Exec | Digital Transformation
Agfa Healthcare has signed a new agreement with DataFirst, a software engineering firm based in Raleigh, N.C., to provide data migration service capabilities and archival storage technologies for healthcare facilities.

Cardiology data migration often places a substantial demand on legacy technology (i.e. jukebox technology, DVD, MOD, etc.) as well as the limited IT resource pool in today's hospital environment. Utilizing DataFirst's Hyper-Migration, Agfa said it can speed the process for facilities compared with standard DICOM query migrations.

In addition to providing migration services, Agfa also will provide end-to-end support, upgrading the archive hardware to industry standard technology, and non-imaging datasets like HL7 reports can be migrated as well.

Justine Varieur Cadet

Related Content

2024 in AI weirdness: ‘Insane’ ChatGPT and mutant rat genitals were only the beginning
10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.